NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
NewAmsterdam Pharma (Nasdaq: NAMS) said it will present at AAIC 2026 in London data on obicetrapib, an oral low-dose CETP inhibitor, for early Alzheimer’s prevention. The company cites a BROADWAY biomarker analysis (n=1,535; ApoE4 carriers n=367) showing lower 12-month p-tau217 changes vs placebo (p=0.025; p=0.022) and says safety was comparable to placebo. PREVAIL enrollment (9,500+ patients) was completed in April 2024.
How this was made
The 30-second read
Why it matters
The article provides concrete AAIC 2026 presentation topics and specific biomarker findings (p-tau217) with statistical significance versus placebo, which can influence near-term sentiment and positioning for the company’s AD-prevention narrative.
Market read
Conference scheduling plus statistically significant p-tau217 biomarker results vs placebo can support incremental bullish positioning, but it is not a new clinical-outcome or regulatory catalyst.
What to watch
The update is presentation-focused and does not include a new safety analysis for the AD biomarker population; investors may wait for full trial endpoints or additional confirmatory data.
Background
NewAmsterdam Pharma is developing obicetrapib, an oral low-dose CETP inhibitor, and is running Phase 3 cardiovascular outcomes (PREVAIL) while exploring Alzheimer’s prevention biomarker effects in BROADWAY.
Ticker impact
NewAmsterdam will present AAIC 2026 data on obicetrapib, including statistically significant lower p-tau217 changes vs placebo over 12 months in BROADWAY.
Near-term: modest positive bias as investors price in continued biomarker progress; larger repricing would likely require new efficacy/safety endpoints beyond biomarker subsets.
The article discloses specific biomarker results (p-values, sample sizes) and the planned conference schedule, but it is still a presentation/biomarker-focused update rather than a new regulatory or primary efficacy outcome.
Market effects
Reinforces investor attention on CETP inhibitors and lipid-mediated pathways as potential Alzheimer’s prevention approaches; limited direct read-across to other biopharma names.
Primarily impacts US-listed small/mid-cap biotech sentiment; conference-driven narrative may influence European biotech peers with AD biomarker programs.
Moderate global relevance for Alzheimer’s prevention research; likely confined to companies with late-stage AD-prevention or biomarker programs.
Counterpoint
Biomarker subset analyses (not controlled for baseline differences) may not translate into clinical benefit, so the market may discount the signal until hard outcomes are reported.
Key entities
- companyNewAmsterdam Pharma Company N.V.
Nasdaq-listed biopharmaceutical developing obicetrapib; subject of the AAIC 2026 presentation announcement.
- drugObicetrapib
Oral low-dose CETP inhibitor; the company’s candidate for Alzheimer’s prevention biomarker read-through.
- clinical_trialBROADWAY Trial
Phase 3 study in which the company reports statistically significant lower p-tau217 changes vs placebo over 12 months in the AD biomarker analysis.
- conferenceAAIC 2026
Alzheimer’s Association International Conference where the company will present the data in London (July 12–15, 2026).
